9 results about "Rheumatoid factor" patented technology

The present invention relates to the technical field of biological detection, and discloses an interleukin chemiluminescence detection kit and a detection method thereof, the kit comprises: interleukin magnetic particles coated with an interleukin antibody, the use concentration of the interleukin magnetic particles being 0.1-1 mg / mL; the interleukin luminous marker is an interleukin labeled antibody labeled by acridinium ester, and the use concentration of the interleukin luminous marker is 0.01 to 5 [mu] g / mL; and the interleukin analysis buffer solution contains a composite anti-interference component and is used for inhibiting the non-specific reaction of endogenous interfering substances in the sample to be detected. According to the present invention, the composite anti-interference component is introduced into the analysis buffer solution, such that the non-specific reaction of the heterotropism antibody, the human anti-mouse antibody, the rheumatoid factor and other endogenous interfering substances in the sample can be effectively inhibited, the detection background signal and the false positive rate are significantly reduced, and the detection accuracy under the complex sample matrix is improved.

The invention relates to the technical field of medical examination, in particular to a stable compound type special protein control product and a preparation method thereof.The preparation method comprises the steps that purified water is taken, a buffer solution, a protective agent, a first stabilizer, a chelating agent, C-reactive protein, antistreptolysin O, rheumatoid factors and retinol binding protein are sequentially added, the mixture is fully stirred till being completely dissolved, and the stable compound type special protein control product is obtained; putting into a constant-temperature box for aging to obtain a dissolving solution; taking out the dissolved solution, standing to room temperature, and filtering by using a peristaltic pump and a bag type filter to obtain a filtrate; and sequentially adding a second stabilizer, cystatin C protein, a third stabilizer, an ion balance agent, lipoprotein (a) and a preservative into the filtrate, and adjusting the pH value to obtain the composite special protein control product. The method can be used for quality control of biochemical item detection processes of retinol binding protein, cystatin C protein, C-reactive protein, antistreptolysin 'O', rheumatoid factors and lipoprotein (a) at the same time.

The invention discloses application of urine microprotein in rheumatoid arthritis disease activity diagnosis, and belongs to the field of rheumatoid arthritis disease activity detection. The method comprises the following steps: detecting erythrocyte sedimentation rate by adopting a Westermann method, detecting C-reactive protein, rheumatoid factors and anti-cyclic citrulline polypeptide antibodies by adopting a full-automatic biochemical analyzer, measuring each urine microprotein by adopting an immune transmission turbidimetry, and evaluating the prediction effect of each urine microprotein on the activity of the rheumatoid arthritis disease through an ROC curve. Results show that IgG, mAlb and beta2-MG levels of rheumatoid arthritis patients are obviously higher than those of healthy people. ESR and CRP in a patient with rheumatoid arthritis are in direct proportion to IgG, mAlb and beta2-MG. The IgG, the mAlb and the beta2-MG are in positive correlation with the RF. Therefore, the early-stage urine microprotein indexes of the rheumatoid arthritis patients are abnormally increased, the diagnosis sensitivity of joint detection is high, and the joint detection has a relatively high diagnosis value on the disease activity of the rheumatoid arthritis.

The application discloses a method for constructing a spontaneous rheumatoid arthritis animal model, and the rheumatoid arthritis phenotype of the mouse is spontaneously generated by knocking out PPARgamma in the skin keratinocytes of the joint part, including joint swelling, joint synovial thickening, inflammatory cell infiltration, anti-cyclic citrullinated polypeptide antibody increase, and rheumatoid factor increase, so that the clinical symptoms of the rheumatoid arthritis are simulated, and an important tool is provided for the related research of the rheumatoid arthritis.

The present invention relates to the field of in vitro diagnostic technology, and more particularly to a rheumatoid factor blocker, a preparation method thereof, and an immunoassay kit. The preparation method comprises the following steps: dissolving a compound of formula I in a first solvent to prepare a first solution; dissolving a compound of formula II in a second solvent to prepare a second solution; mixing the first and second solutions, reacting the compound of formula I with the compound of formula II, and collecting the reaction product. The preparation method of the present invention can produce a rheumatoid factor blocker capable of reducing RF interference with immunoassays.

The present application relates to a kind of preparation methods of stable rheumatoid nephrology composite calibration quality control raw materials, comprising the following steps;Step 1, preparation composite quality control matrix liquid;Step 2, preparation quality control raw material additive;Step 3, the prepared quality control raw material additive is mixed into composite quality control matrix liquid;Step 4, the mixed solution is filtered and can be used.The present application uses rheumatoid factor (RF), C-reactive protein (CRP), anti-streptolysin (ASO), alpha 1 microglobulin (alpha 1-mg), beta 2 microglobulin (beta 2-mg) high-purity antigen as raw material, through composite debugging and assignment, and liquid protective agent (Tween 80, trehalose, anhydrous calcium chloride, ETDA, glycerol) is added, to obtain a kind of stable rheumatoid nephrology composite calibration quality control raw material.The rheumatoid nephrology composite calibration quality control raw material prepared has good stability, simple preparation process, low cost, high process repeatability, can be industrialized production, has potential and extensive application value in clinical diagnosis, in vitro diagnosis.

Provided herein are methods of treating rheumatoid arthritis characterized by low acute phase reactant (APR) or positive rheumatoid factor (RF) with anti-CD22 antibodies that selectively target pathogenic B cells, such as suciraslimab. Exemplary compositions and methods of treatment are described herein.

The invention provides a homogeneous chemiluminescence determination kit and a quantitative determination method of pepsinogen I. The kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 comprises a luminescence donor molecule coupled with a first antibody of pepsinogen I and a reaction buffer solution; and the R2 reagent comprises a light-emitting receptor molecule coupled with a pepsinogen I second antibody and a reaction buffer solution. A donor / receptor double-labeled antibody sandwich reaction is adopted, one-step incubation is achieved, solid-phase separation and washing are not needed, the process is remarkably simplified, and the detection time is shortened; by collecting the luminous intensity at 620 nm and 665 nm and quantifying the luminous intensity by a specific value signal, errors caused by sample turbidity, color and volume fluctuation and instrument drift can be effectively corrected; meanwhile, a protein blocking agent, a chelating agent and a heterophilic antibody blocking component are introduced into a reaction buffer system, interference of non-specific adsorption and rheumatoid factors / heterophilic antibodies is reduced, and adaptability to complex matrixes such as bile fluid and serum / plasma is enhanced.

A kit and method are described herein for detecting an analyte in a body fluid sample. The kit and method use a test-specific blocking antibody for reduction of interferences, for example as caused by heterophilic antibodies or rheumatoid factors.